Background/Aims: Early repolarization syndrome (ERS) has been recently recognized as early repolarization pattern with idiopathic ventricular fibrillation. However, the genetic background of ERS has not been fully understood. Methods: A Chinese family with sudden cardiac death associated with ERS was investigated. Direct sequencing of ERS susceptibility genes was performed on the proband and family members. Whole-cell patch-clamp methods were used to characterize the mutant channel expressed in HEK 293 cells. Results: One missense mutation (p. K801T) was found in the hERG (KCNH2 gene) by the direct sequencing of candidate genes. Whole cell voltage clamp studies of the K801T mutation in HEK 293 cells demonstrated a 1.5-fold increase in maximum steady state current (37.2±7.3 vs 20.3±4.4 pA/pF) that occurred at a 20 mV more positive potential compared to the wild type channels. The voltage dependence of inactivation was significantly shifted in the positive voltage direction (WT -59.5±1.4 vs K801T -44.3±1.2 mV). Kinetic analysis revealed slower inactivation rates of K801T, but faster rates of activation and deactivation. The hERG channel blockers tested inhibited K801T-hERG channel in concentration response, and the potencies of these drugs can be rank-ordered as follows: quinidine> disopyramide> sotalol> flecainide. Conclusion: Our study indicated that the K801T mutation caused the gain of function of hERG channels that may account for the clinical phenotype of ERS. Quinidine and disopyramide could improve the function of K801T-hERG mutant channel, and may be therapeutic options for patients with the K801T hERG mutation.
Introduction
Early repolarization pattern (ERP) on the electrocar diogram (ECG) is defined as J point elevation ≥0.1 mV or QRS notching or slurring in at least 2 contiguous inferior and/or lateral leads [1] . It is prevalent in 2.3% to 29.3% of the population depending on race, age and gender category [2, 3] . Several recent reports and our previous studies indicated that ERP was associated with increased risk for ventricular fibrillation (VF) and sudden cardiac death (SCD) in the general population and in patients with structural heart disease [2, [4] [5] [6] . The 2015 ESC Guidelines for the management of patients with ventricular arrhythmias defined early repolarization syndrome (ERS) as the presence of ERP with resuscitation from a documented episode of unexplained VF or polymorphic ventricular tachycardia (VT) [7] .
The autosomal dominant inheritance nature of the ERP has been suggested by casecontrol studies as well as by studies in the general population, but the familial inheritance of malignant ERS has not been clearly demonstrated [4, 8] . So far, rare genetic variants in genes governing cardiac repolarization, including SCN5A, KCNJ8, and L-type calcium channel subunits, have been shown to be causally associated with ERS [9] . Human hERG (KCNH2 gene) encodes α-subunit of the rapid component of the delayed rectifier K+ channel, which plays an important role in regulating the repolarization of the cardiac action potential [10] . In the present study, a Chinese family with the clinical phenotype of ERS was found to have a novel mutation in the hERG gene, K801T, and we report herein that this newly discovered mutation in hERG causes a substantial gain-of-function. We also tested the effects of antiarrhythmic drugs which could prolong cardiac repolarization on the mutant K801T hERG channels expressed in HEK 293 cells.
Materials and Methods

Clinical investigation
The proband with a strong family history of sudden cardiac death was referred to us for further evaluation. A complete battery of studies including medical history, physical examination, electrolytes, 12-lead ECG, 24-hour Holter monitoring, echocardiography, coronary angiography and genetic testing were done. The study conformed to the principles outlined in the Declaration of Helsinki. This study was approved by the institutional review board, and the patients provided written informed consent for participation. 
Electrophysiological analysis in transfected HEK 293 cells
Functional characterization of WT-and mutant hERG-channels was performed by voltage clamp techniques using transfected HEK 293 cells. Patch clamp recordings were made using low-resistance electrodes (<3 MOhm), and a routine series resistance compensation by an Axopatch 200B amplifier (Axon Instruments Inc, Foster City, CA) was performed to minimize voltage-clamp errors. The patch pipette solution contained (mmol/L): 140 KCl, 10 NaCl, 1 MgCl 2 , 10 HEPES and 10 EGTA (pH 7.3 with KOH). The extracellular bath solution contained (mmol/L): 140 NaCl, 5 KCl, 1MgCl2, 2 CaCl2, 10 HEPES and 10 glucose (pH 7.4 with NaOH). Membrane currents were recorded in the whole cell configuration using an Axopatch 200B amplifier controlled by pCLAMP10.3 software (Molecular Devices, Sunnydale, CA). Specific voltageclamp protocols used to determine voltage dependence of activation, inactivation, and recovery from inactivation are illustrated in the figure legend. All experiments were performed at room temperature. Normalized activation and inactivation curves were fitted by a single component Boltzmann model:
, where I is the tail current amplitude following test potential V m , I max is the maximum current density of activation or inactivation, V 0.5 is the half-maximum activation or inactivation voltage, and k is the slope factor for the relationship.
The effects of hERG channel blockers were determined using a two step protocol. hERG potassium currents were elicited by 4-s voltage pulses to +20 mV from a holding potential of -80 mV, followed by a repolarizing ramp to -80 mV, eliciting a large outward tail current. Steady current at the end of the first step and the peak tail current were determined before and during the response to the blockers. The concentration-response relationship of hERG channel blockers was quantified by fitting the data using the Hill equation:
, where D is the drug concentration, p is the Hill coefficient, IC 50 is the concentration for 50% inhibition. IC 50-steady and IC 50-tail are the concentration for 50% inhibition of steady current and tail current, respectively [12] .
Statistical analysis
Data are represented as the means±stan dard error of the mean (SEM) unless otherwise indicated. Statistical analysis of the data was performed using a Student's t test for paired data or a one-way ANOVA for comparisons of multiple means with statistical software SPSS 19.0. Statistical significance was set at P<0.05.
Results
Clinical characteristics
The proband, a 42-year-old male patient was admitted to the First Affiliated Hospital of Sun Yat-Sen University due to a history of recurrent syncope at rest (once or twice every year since 5 years ago). His previous medical records indicated that he often presented with chest discomfort and palpitation, followed by which transient loss of consciousness occurred. The ECG that was obtained at the emergency department exhibited positive QRS complex, J-point elevation by 0.2mV, descending ST segment and negative T waves in inferior (II, III and aVF) leads (Fig. 1A) . During the admission process, VT and subsequent VF episode, which were terminated successfully by direct current cardioversion, were documented on the ECG obtained in the ward (Fig. 1B, 1C ). There was no difference in clinical state that may explain the marked J waves in ECG. Myocardial infarction was excluded by cardiac enzyme tests and coronary angiography. Structural abnormalities were excluded by echocardiography, and electrolyte disturbances were excluded by laboratory tests. According to the clinical manifestations, he was diagnosed with ERS and received an implantable cardioverter defibrillator implantation.
The family pedigree is presented in Fig. 1D . A total of 9 family members were evaluated clinically and genetically, and four of them suffered SCD ( Fig. 1D ; I-1, II-1, II-2, II-4) at relatively young ages (35 to 52 years old) all of which occurred at night. Other family members were asymptomatic. In the ECG of the proband's 31-year-old sister (III-2), terminal QRS notches in leads II, III and aVF (J-point elevation>0.1mV) with horizontal ST-segment were observed (Fig. 1E) . The ERP ECG pattern with terminal QRS notches or slurrings was also observed in both his younger cousins (Fig. 1E ). In addition, ERP phenotype in inferior and lateral leads was also observed in the proband's decreased mother (II-2) (Fig. 2) . The QTc interval for the family members with ERP were shorter than the ethnically matched controls (384±12 ms vs. 415±9ms, p=0.02).
The result of mutation analysis
Genetic studies of the patients' DNA excluded mutations in SCN5A, KCNQ1, KCNE1, KCNE2, KCNE3, HCN4, CACNA1C, CACNB2. A single base pair substitution (A to C substitution at nucleotide 2402, c.2402 A>C) was found in the hERG gene of the proband (Fig. 3A) , resulting in an amino acid change from lysine to threonine at position 801 (p.K801T) in the hERG potassium channel. The schematic topology in Fig. 3C depicts location of this mutation which is located in C-terminus of hERG protein, and is therefore likely to influence function. The same mutation was present in his younger sister and two cousins. However, this mutation was not observed in the proband's father, indicating the K801T mutation of the proband could have been inherited from his decreased mother. The K801T substitution was not present in any of 150 control subjects of the same ethnic background, and has not been reported according to the NHLBI Exome Sequencing Project, Exome Variant Server (http://evs.gs.washington.edu/EVS/), suggesting that the mutation is associated with the phenotype. 
Cellular electrophysiology
To determine the effects of the K801T mutation on hERG channel function and its contribution to the clinical phenotype, we expressed WT-and K801T-hERG constructs in HEK 293 cells for electrophysiological analysis. Whole-cell recordings showed that both WTand K801T-hERG currents elicited by sequential depolarizing pulses exhibit slow initial rates of activation with peak current increasing with voltage to a maximum. With further increases in voltage, the current decreases because of the rapid onset of inactivation (rectification). WT and K801T recordings also displayed the typical large tail currents generated by inactivated channels rapidly reopening on repolarization.
Current from the cells expressing the two hERG constructs was measured at the end of the first voltage clamp step, normalized by cell capacitance and averaged. A comparison of the steady current density-voltage relations between the WT-and K801T-hERG channels is shown in Fig 4B. The peak current occurred at about +10 mV for WT-hERG and at about +30 mV for K801T-hERG, and was approximately 1.5-fold greater for K801T-(37.2±7.3 pA/pF, n=25) compared to WT-hERG (20.3±4.4 pA/pF, n=18, P<0.001). Fig. 4C shows activation curves derived from tail currents for WT-and K801T-hERG channels, 
fitted with a Boltzmann model. The half-activation voltage of K801T-hERG was -18.5±0.9 mV, whilst for WT-hERG this was -6.0±1.2 mV (P<0.001), indicating a significant voltage shift in the K801T-hERG compared to WT. The corresponding k values for K801T-and WT-hERG channels were 6.6±0.8 mV and 9.2±1.0 mV, respectively (p<0.001). We used an ''envelope of tails protocol'' to investigate effects of the K801T mutation on the time-course of hERG activation. Mono-exponential fits to the data yielded a τ activation of 128.3 ±3.5 ms for WT-hERG and of 121.2±4.3ms for K801T-hERG (n=18 and 25 cells respectively; P=0.02), indicating that activation rate for K801T-hERG was faster than WT-hERG during this protocol (Fig. 4E) . (Fig. 5D) . The time-course of development of inactivation for WT and K801T-hERG was compared by mono-exponential fitting of the decline of transient currents elicited following the repolarizing step to -120 mV. This yielded τ-values for WT and K801T-hERG inactivation of 1.6±0.2 ms and 3.3±0.4 ms respectively ( Fig. 5F ; n=12 and 16 respectively; p=0.001). Table 1) .
The IC 50 of the four drugs in K801T-hERG channels was significantly higher than that of WT-hERG channels, indicating the inhibition of hERG blockers on K801T-hERG channels was weaker than WT-hERG channels. All four drugs tested inhibited WT-hERG and K801T-hERG in concentration response, and the potencies of these drugs can be rank-ordered as follows: quinidine> disopyramide> sotalol> flecainide. A Hill coefficient close to 1.0 was obtained for each drug, indicating a single binding site to the hERG channel. 
Discussion
We report herein a novel mutation, K801T, in the hERG gene in a single Chinese family with ERS. Our results show that the K801T mutation leads to a significant increase in hERG current, a significant negative shift in the voltage dependence of activation, faster rate of activation and deactivation, and a positive shift in the voltage dependence of inactivation, indicating that gain-of-function mutation of hERG channel might be a genetic basis for ERS. The hERG channel blockers, including quinidine, disopyramide, sotalol and flecainide, inhibited K801T-hERG channel in concentration response.
It is important to emphasize that, although ERP is common finding in the general population, only a small subset of patients with this pattern have an increased risk for SCD. Currently, however, there are no tools available, including ECG phenotype, provocative drug testing and electrophysiological studies to improve risk stratification [13] . Interestingly, ERP and Brugada syndrome (BrS) share some common clinical traits, including the mean age of onset, male predominance, variability of the ECG alterations, and response to drugs or autonomic modulation. Genetically, loss-of-function mutations in SCN5A, CACNA1C, CACNB2 and CACNA2D, and gain-of-function mutations in KCNJ8 and hERG have been identified to be associated with BrS [14] . Given these evidences, it is highly likely that a genetic basis for ERS also exists.
The first genetic study of ERS was a case report that described a rare variant in KCNJ8, responsible for the pore forming subunit of the cardiac I K-ATP channel, in a 14-year-old girl presenting with an ERP and frequent VF episodes [15] . Burashnikov et al. reported four patients with ERS, carrying loss of function mutations in the α1 and β2 and α2δ subunits of the cardiac L-type calcium channel (CACNA1C, CACNB2, and CACNA2D1) [16] . The most recent addition to the genes associated with ERS is SCN5A, the gene that encodes the α subunit of the cardiac sodium channel [17] . Our results identify a novel hERG mutation to produce a remarkable gain of function and provide a novel genetic basis for the ERS. The K801T mutation of hERG gene was only found in the proband and affected family members with marked ERP and was not present in a control population of 150 individuals, there might be a causal relationship between the mutation and ERS. As could be predicted from gain-offunction hERG mutations that lead to BrS, the K801T mutation associated with ERS in the family reported herein was associated with a gain-of-function.
The hERG channel has previously been linked to an increase in outward repolarizing current responsible for the short QT syndrome and BrS [18, 19] . In patients with BrS, several gain-of-function hERG mutations (G873S, W927G, N985S and R1135H) have been reported to increase the I Kr current densities and the susceptibility to all-or-none repolarization (loss-of-dome of action potentials) [18, 20] . Given the similarity of mechanisms between ERS and BrS, we proposed the mutation-induced increase in I Kr during initial activation may also contribute to the premature repolarization in patients with ERS. We next investigated whether the K801T change itself could be responsible for these effects. Electrophysiological characterization of the T801-hERG channel revealed that this channel exhibited biophysical properties quite different from those of the K801-hERG channel, with the peak tail current increasing by 1.5 folds, and voltage dependence of steady-state activation shifting by 12 mV, and time courses of deactivation accelerating by approximately twofold. Of note, the rates of activation and deactivation were also faster in T801-hERG channel than in T801-hERG channel. Despite the effects were relatively small, they still reach statistical significance. These hasten repolarization, which would translate into ERP phenotype on the surface ECG and increase the vulnerability to VF.
The K801 residue in hERG is evolutionary highly conserved from mouse and rat to human, suggesting that replacing this codon with threonine might influence the function of the hERG channel. The K801T variant is located in the C-terminus of the hERG channel, a site that plays a critical role in cardiac repolarization regulating the outward K+ current Cellular Physiology and Biochemistry
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by an interaction with the N-terminus, and delaying the channel inactivation by a knock-off mechanism [21] . In addition, the substitution of a basic lysine for a neutral threonine might also result in a change of ionic properties of the involved region of hERG channel. Although pharmacologic therapy of ERS has not been systematically assessed, quinidine has been demonstrated to exert an ameliorative effect in preventing or quieting arrhythmias associated with ERS [15] . In addition, The Class III antiarrhythmic drug sotalol has been found to be effective against the hERG mutation in short QT syndrome [19] . We therefore compared between WT and K801T-hERG the potency of hERG current inhibition for class I and class III antiarrhythmic drugs under conventional voltage clamp. In our experiment, quinidine and disopyramide exhibit greater blocking potency than sotalol and flecainide on both WT and K801T-hERG channel, indicating quinidine and disopyramide may be worthy of investigation as a potential treatment for ERS. We also found the four drugs tested exhibited weaker inhibition potency on K801T-hERG channels than on WT-hERG channels, and this suggests the K801T missense mutation could decrease the affinity and interaction of the channel for drugs with class I and class III antiarrhythmic action. Previous studies demonstrated many antiarrhythmic drugs bind to their receptors on hERG channels in the open state, which is thought to be stabilized by inactivation of the channel [22] . The shift of K801T hERG channel inactivation to more positive voltages has been suggested to be the explanation for the decreased affinity of these channels to class I and class III antiarrhythmic drugs [19] .
Conclusion
In conclusion, we investigated a rare ERS family with a high incidence of SCD, in which we found a pathogenic mutation in hERG (p.K801T) with gain-of-function. The targeted mutation screening might provide a promising prognostic tool for risk stratification of patients with ERP. Quinidine and disopyramide, in our present study, could improve the function of K801T-hERG mutant channel. However, further clinical trials are needed to elucidate the therapeutic feasibility to human.
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